Literature DB >> 24476767

CALR mutations are infrequent in WHO-defined refractory anemia with ring sideroblasts.

M M Patnaik1, A Belachew1, C Finke1, T L Lasho1, C A Hanson1, A Tefferi1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24476767     DOI： 10.1038/leu.2014.47

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  10 in total

1.  SF3B1 mutations in primary myelofibrosis: clinical, histopathology and genetic correlates among 155 patients.

Authors:  T L Lasho; C M Finke; C A Hanson; T Jimma; R A Knudson; R P Ketterling; A Pardanani; A Tefferi
Journal:  Leukemia       Date:  2011-11-08       Impact factor: 11.528

2.  Prognostic irrelevance of ring sideroblast percentage in World Health Organization-defined myelodysplastic syndromes without excess blasts.

Authors:  Mrinal M Patnaik; Curtis A Hanson; Nanna H Sulai; Janice M Hodnefield; Ryan A Knudson; Rhett P Ketterling; Terra L Lasho; Ayalew Tefferi
Journal:  Blood       Date:  2012-04-26       Impact factor: 22.113

3.  CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons.

Authors:  A Tefferi; T L Lasho; C M Finke; R A Knudson; R Ketterling; C H Hanson; M Maffioli; D Caramazza; F Passamonti; A Pardanani
Journal:  Leukemia       Date:  2014-01-09       Impact factor: 11.528

4.  Essential thrombocythemia with ringed sideroblasts: a heterogeneous spectrum of diseases, but not a distinct entity.

Authors:  Annette Schmitt-Graeff; Juergen Thiele; Irina Zuk; Hans Michael Kvasnicka
Journal:  Haematologica       Date:  2002-04       Impact factor: 9.941

5.  SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value.

Authors:  Mrinal M Patnaik; Terra L Lasho; Janice M Hodnefield; Ryan A Knudson; Rhett P Ketterling; Guillermo Garcia-Manero; David P Steensma; Animesh Pardanani; Curtis A Hanson; Ayalew Tefferi
Journal:  Blood       Date:  2011-11-17       Impact factor: 22.113

6.  Somatic mutations of calreticulin in myeloproliferative neoplasms.

Authors:  Thorsten Klampfl; Heinz Gisslinger; Ashot S Harutyunyan; Harini Nivarthi; Elisa Rumi; Jelena D Milosevic; Nicole C C Them; Tiina Berg; Bettina Gisslinger; Daniela Pietra; Doris Chen; Gregory I Vladimer; Klaudia Bagienski; Chiara Milanesi; Ilaria Carola Casetti; Emanuela Sant'Antonio; Virginia Ferretti; Chiara Elena; Fiorella Schischlik; Ciara Cleary; Melanie Six; Martin Schalling; Andreas Schönegger; Christoph Bock; Luca Malcovati; Cristiana Pascutto; Giulio Superti-Furga; Mario Cazzola; Robert Kralovics
Journal:  N Engl J Med       Date:  2013-12-10       Impact factor: 91.245

7.  Spliceosome mutations involving SRSF2, SF3B1, and U2AF35 in chronic myelomonocytic leukemia: prevalence, clinical correlates, and prognostic relevance.

Authors:  Mrinal M Patnaik; Terra L Lasho; Christy M Finke; Curtis A Hanson; Janice M Hodnefield; Ryan A Knudson; Rhett P Ketterling; Animesh Pardanani; Ayalew Tefferi
Journal:  Am J Hematol       Date:  2013-01-18       Impact factor: 10.047

8.  Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia.

Authors:  Giada Rotunno; Carmela Mannarelli; Paola Guglielmelli; Annalisa Pacilli; Alessandro Pancrazzi; Lisa Pieri; Tiziana Fanelli; Alberto Bosi; Alessandro M Vannucchi
Journal:  Blood       Date:  2013-12-26       Impact factor: 22.113

9.  Differential prognostic effect of IDH1 versus IDH2 mutations in myelodysplastic syndromes: a Mayo Clinic study of 277 patients.

Authors:  M M Patnaik; C A Hanson; J M Hodnefield; T L Lasho; C M Finke; R A Knudson; R P Ketterling; A Pardanani; A Tefferi
Journal:  Leukemia       Date:  2011-10-28       Impact factor: 12.883

10.  Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2.

Authors:  J Nangalia; C E Massie; E J Baxter; F L Nice; G Gundem; D C Wedge; E Avezov; J Li; K Kollmann; D G Kent; A Aziz; A L Godfrey; J Hinton; I Martincorena; P Van Loo; A V Jones; P Guglielmelli; P Tarpey; H P Harding; J D Fitzpatrick; C T Goudie; C A Ortmann; S J Loughran; K Raine; D R Jones; A P Butler; J W Teague; S O'Meara; S McLaren; M Bianchi; Y Silber; D Dimitropoulou; D Bloxham; L Mudie; M Maddison; B Robinson; C Keohane; C Maclean; K Hill; K Orchard; S Tauro; M-Q Du; M Greaves; D Bowen; B J P Huntly; C N Harrison; N C P Cross; D Ron; A M Vannucchi; E Papaemmanuil; P J Campbell; A R Green
Journal:  N Engl J Med       Date:  2013-12-10       Impact factor: 91.245
  10 in total
  8 in total

1.  Low frequency of calreticulin mutations in MDS patients.

Authors:  M Heuser; V Panagiota; C Koenecke; B Fehse; H Alchalby; A Badbaran; R Shahswar; M Stadler; M Eder; G Göhring; A Trummer; T Schroeder; G Kobbe; C Thiede; U Platzbecker; B Schlegelberger; N Kroeger; A Ganser; F Thol
Journal:  Leukemia       Date:  2014-05-21       Impact factor: 11.528

Review 2.  Unfolding the Role of Calreticulin in Myeloproliferative Neoplasm Pathogenesis.

Authors:  Ross L Levine; Elodie Pronier; Tiffany R Merlinsky
Journal:  Clin Cancer Res       Date:  2019-01-17       Impact factor: 12.531

Review 3.  Refractory anemia with ring sideroblasts (RARS) and RARS with thrombocytosis: "2019 Update on Diagnosis, Risk-stratification, and Management".

Authors:  Mrinal M Patnaik; Ayalew Tefferi
Journal:  Am J Hematol       Date:  2019-01-24       Impact factor: 10.047

4.  Distinct clinical characteristics of myeloproliferative neoplasms with calreticulin mutations.

Authors:  Hajnalka Andrikovics; Tunde Krahling; Katalin Balassa; Gabriella Halm; Andras Bors; Magdalena Koszarska; Arpad Batai; Janos Dolgos; Judit Csomor; Miklos Egyed; Andrea Sipos; Peter Remenyi; Attila Tordai; Tamas Masszi
Journal:  Haematologica       Date:  2014-06-03       Impact factor: 9.941

Review 5.  Refractory anemia with ring sideroblasts (RARS) and RARS with thrombocytosis (RARS-T): 2017 update on diagnosis, risk-stratification, and management.

Authors:  Mrinal M Patnaik; Ayalew Tefferi
Journal:  Am J Hematol       Date:  2017-03       Impact factor: 10.047

6.  Calreticulin exon 9 mutations in myeloproliferative neoplasms.

Authors:  Jung-Sook Ha; Yu-Kyung Kim
Journal:  Ann Lab Med       Date:  2014-12-08       Impact factor: 3.464

7.  Lenalidomide induced durable remission in a patient with MDS/MPN-with ring sideroblasts and thrombocytosis with associated 5q- syndrome.

Authors:  Ahmed Alshaban; Osvaldo Padilla; Alexander Philipovskiy; Javier Corral; Meghan McAlice; Sumit Gaur
Journal:  Leuk Res Rep       Date:  2018-08-24

Review 8.  The Contemporary Approach to CALR-Positive Myeloproliferative Neoplasms.

Authors:  Tanja Belčič Mikič; Tadej Pajič; Samo Zver; Matjaž Sever
Journal:  Int J Mol Sci       Date:  2021-03-25       Impact factor: 5.923
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.